Merck Stock: Keytruda Growth Moderation & Exclusivity Outlook
Merck & Co. (NYSE: MRK) faces slowing domestic growth for its flagship cancer treatment Keytruda as management guides to moderation and European sales face legal hurdles in eight markets. Investors are weighing whether pipeline drivers such as WINREVAIR and WELIREG can offset upcoming patent cliffs through the early 2030s.
If Keytruda sales growth moderates, watch because its valuation stability relies on newer drugs like WINR and free cash flow generation exceeding dividend requirements. Compare performance against and .